Clover Health Investments, Corp. CLOV
- Market cap
- $2.5B
- P/E
- 0.0×
Follow CLOV
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 9.87 | 3.68 | 0.86 | 0.71 | 0.61 | 2.12 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 17.20 | 28.85 | 4.11 | 1.63 | 4.71 | 4.87 |
High Price
|
|||
| — | — | — | — | 458 | 680 | 656 | 552 | 570 | 724 |
Employees
|
|||
| — | — | — | 0 | 1 | 2 | 2 | 2 | 2 | 3 |
Revenue/Emp
|
|||
| — | — | — | 462 | 673 | 1,472 | 1,097 | 1,261 | 1,371 | 1,924 |
Revenue
|
|||
| — | — | — | 3.37% | 12.31% | (5.38%) | 9.44% | 20.30% | 26.61% | 18.50% |
Gross Margin
|
|||
| — | — | — | (364) | (136) | (588) | (255) | (210) | (46) | (86) |
EBT
|
|||
| — | — | — | (78.69%) | (20.27%) | (39.93%) | (23.22%) | (16.67%) | (3.37%) | (4.45%) |
EBT Margin
|
|||
| — | 0 | — | (364) | (136) | (588) | (340) | (213) | (43) | (86) |
Net Income
|
|||
| — | — | — | 14 | 21 | 15 | 0 | (2) | (1) | 0 |
Depreciation
|
|||
| — | — | — | 5.26 | 7.59 | 3.56 | 2.30 | 2.61 | 2.80 | 3.76 |
Revenue/Sh
|
|||
| — | — | — | (4.14) | (1.54) | (1.42) | (0.71) | (0.44) | (0.10) | (0.17) |
Earnings/Sh
|
|||
| — | — | — | (1.82) | (1.34) | (0.68) | (0.43) | (0.30) | 0.07 | (0.13) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | (1.82) | (1.34) | (0.69) | (0.44) | (0.30) | 0.07 | (0.13) |
Free CF/Sh
|
|||
| — | — | — | 0.00 | (6.91) | 1.31 | 0.75 | 0.59 | 0.70 | 0.60 |
Book Value/Sh
|
|||
| — | — | — | 88 | 89 | 413 | 476 | 482 | 490 | 512 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.00 | 2.21 | 1.04 | 0.41 | 0.37 | 1.13 | 0.63 |
PS Ratio
|
|||
| — | — | — | 121,753.54 | 0.00 | 2.85 | 1.27 | 1.62 | 4.52 | 3.90 |
PB Ratio
|
|||
| — | — | — | 0.00 | 2.26 | 0.65 | 0.11 | 0.18 | 0.97 | 0.57 |
EV/Sales
|
|||
| — | — | — | 0.00 | (12.73) | (3.40) | (0.59) | (1.59) | 39.84 | (15.76) |
EV/FCF
|
|||
| — | — | — | (160) | (118) | (282) | (204) | (145) | 35 | (67) |
Op' Cash Flow
|
|||
| — | — | — | 0 | (1) | (1) | (4) | (1) | (2) | (2) |
Capex
|
|||
| — | — | — | (160) | (119) | (283) | (208) | (145) | 33 | (69) |
FCF
|
|||
| — | — | — | 0 | 26 | 380 | 193 | 167 | 130 | 99 |
Working Cap'
|
|||
| — | — | — | — | 127 | 20 | 6 | 1 | — | — |
Total Debt
|
|||
| — | — | — | — | 31 | (595) | (329) | (235) | (222) | (120) |
Net Debt
|
|||
| — | — | — | 0 | (613) | 539 | 357 | 286 | 341 | 309 |
Sh' Equity
|
|||
| — | — | — | (725,298.11%) | (102.03%) | (96.51%) | (38.60%) | (30.94%) | (7.47%) | (15.25%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | (646.22%) | (249.05%) | (23.91%) | (28.37%) |
ROIC
|
|||
| — | — | — | 117.88% | 44.48% | 1,591.19% | (75.78%) | (66.34%) | (13.71%) | (26.33%) |
ROE
|
|||
Clover Health Investments, Corp. peers in Healthcare Plans
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PGNY Progyny, Inc. | $2.0B | 26.2× | Compare |
| ALHC Alignment Healthcare, Inc. | $1.6B | 39.1× | Compare |
| OSCR Oscar Health, Inc. | $8.9B | 17.3× | Compare |
| MOH Molina Healthcare, Inc | $10.1B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CNC Centene Corporation | $30.6B | 0.0× | Compare |
| HUM Humana Inc. | $45.7B | 37.4× | Compare |
| CI Cigna Group | $69.9B | 11.3× | Compare |
| ELV Elevance Health, Inc. | $86.4B | 17.6× | Compare |
Clover Health Investments, Corp. (CLOV) key facts
- Clover Health Investments, Corp. (CLOV) is a Healthcare Plans company in the Healthcare sector, listed on Nasdaq.
- Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024.
- Clover Health Investments, Corp. reported a net loss of $85.5 million, or a loss of $0.17 per share, for fiscal 2025.
- As of September 25, 2026, CLOV traded at $4.49, a market capitalization of $2.5 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.0× sales.
- Return on equity was −26.3% and debt-to-equity 0.00.
Clover Health Investments, Corp. (CLOV) Latest News
25 Sep
StockStory designates Clover Health (CLOV) as the sole cash-producing stock on its buy list, with IPG Photonics and Lincoln Educational tagged as sells. CLOV shows 36.9% revenue growth over two years, 15.2% annual EPS growth over five years, and a positive 3% free cash flow margin—an inflection point as it scales Medicare Advantage via Clover Assistant. At $4.53, CLOV trades around 30.5x forward P/E. The article frames Clover as at an important crossroads with upside potential, encouraging readers to review its free full report before deciding whether to start a position. In contrast, IPGP is weakening (FCF margin 1.9%, shrinking margins) and LINC faces declining enrollment performance and higher investments to defend market share. Highlights CLOV’s improving free cash flow and growth metrics, potentially nudging sentiment but not signaling a major catalyst.
24 Sep
Clover Health Investments, Corp. announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller to its Board of Directors. Torricelli will join the Audit Committee; Miller will join the Clinical Committee, filling two vacancies and bringing the board to nine. CEO Andrew Toy said the hires strengthen governance and oversight, while Co-founder Vivek Garipalli cited diverse perspectives to advance Clover's mission. Torricelli brings New Jersey roots, federal healthcare policy experience, and prior Clover involvement on the insurance subsidiary board since 2022. Miller is a Johns Hopkins hospitalist and professor with regulatory experience at CMS, FDA, FTC, and MedPAC, and serves on the North Carolina State Health Plan board. Clover's Clover Assistant platform aims to improve care and reduce costs in Medicare Advantage, with Counterpart Health extending capabilities to broader providers. Adds two high-profile board members with policy, clinical, and Medicare expertise, potentially influencing governance and strategic direction.
Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, MedPAC commissioner and Johns Hopkins physician, to its board of directors, effective immediately. Torricelli will join the Audit Committee and Miller the Clinical Committee, filling two vacancies and bringing the board to nine directors. Torricelli brings New Jersey political and policy experience along with familiarity with Clover through the company's insurance subsidiary board since 2022; Miller offers frontline clinical practice and Medicare policy expertise, including CMS, FDA, and FTC experience and MedPAC service. Clover described the hires as strengthening governance and the company's ability to advance its physician-enabled strategy via its Clover Assistant platform, with plans spanning Medicare Advantage plans and Counterpart Health. CEO Andrew Toy and co-founder Vivek Garipalli highlighted the value of diverse perspectives in improving care, efficiency, and member value. Brings MedPAC policy experience and federal policy insight to the board, potentially affecting governance and regulatory outlook.
18 Sep
Clover Health gains PPO edge and cohort improvements as Medicare Advantage pricing tightens. PPO edge and cohort gains signal moderate competitive gains for Clover Health in Medicare Advantage.
15 Sep
ALHC stock tumbles after company silence on Star Ratings, with CLOV shares declining in tandem amid sector scrutiny. ALHC Star Ratings silence triggers short-term CLOV stock drop reflecting market sensitivity to ratings without altering core trajectory.
3 Sep
Clover Health has turned profitable as Medicare membership exploded. Profitability with exploding Medicare membership signals major positive shift in financial performance and trajectory.
14 Aug
Clover Health turned profitable and raised 2026 guidance, strengthening the bull case for CLOV. Profit turnaround plus raised guidance signals major positive shift in financial trajectory and investor outlook.
Five key analyst questions from Clover Health's Q2 earnings call addressed company operations, financial outlook and strategic priorities. Earnings call questions offer targeted insights that can moderately shape near-term investor views on performance.
12 Aug
Clover Health (CLOV) released Q2 2026 earnings call transcript covering financial results and outlook. Earnings call details typically include metrics and guidance that shift company trajectory and sentiment.
11 Aug
Clover Health targets GAAP profitability by 2026, with its AI platform driving Medicare Advantage membership growth and operational efficiency. Profitability target for 2026 plus AI platform scaling Medicare Advantage operations point to major strategic and financial trajectory shifts.
6 Aug
Clover Health Investments, Corp. held its Q2 2026 earnings call outlining quarterly financial results and operational metrics. Earnings call details directly shape near-term stock valuation and investor outlook through reported metrics and guidance.
Clover Health Investments Corp beat revenue expectations in Q2 2026 earnings call with positive operational highlights. Strong revenue beat signals improved financials likely to lift investor sentiment and stock trajectory.
5 Aug
Clover Health Investments reported its second quarter 2026 financial results. Quarterly results directly shape near-term valuation and investor outlook for the company.
Clover Health Investments, Corp. (CLOV) released Q2 earnings call highlights covering financial results, operational metrics, and management commentary on performance and outlook. Q2 earnings updates typically affect short-term market sentiment without fundamentally shifting long-term company trajectory.
Clover Health's Q2 CY2026 sales exceeded estimates, prompting a 10.3% stock increase. Quarterly sales beats can moderately influence stock prices and market perception without fundamentally changing long-term company trajectory.
3 Aug
Clover Health shows improving operational metrics and membership trends, suggesting a possible turnaround for the Medicare Advantage insurer after prior losses and challenges. Signs of operational improvement at Clover Health may moderately affect financial performance and market sentiment without fundamentally altering long-term trajectory.
11 Jul
Clover Health Investments (CLOV) faces a valuation test ahead of its August earnings report. Upcoming earnings create moderate valuation pressure on CLOV without indicating major strategic shifts.
7 Jul
Clover Health's Counterpart Assistant use links to stronger transitions of care metrics and post-hospitalization follow-up performance. Counterpart Assistant data indicates measurable gains in core care continuity operations at Clover Health.
6 Jul
UBS nearly doubled its price target on Clover Health (CLOV). Analyst price target increase can moderately influence short-term market sentiment for Clover Health.
10 Jun
Clover Health (CLOV) stock hits a fresh peak after receiving an unexpected CMS rating. Unexpected CMS rating directly lifts Clover Health stock to new highs and improves outlook.
Court order propels CLOV stock to over 4.5-year highs as retail investors flag potential industry-wide implications. Court order triggers major stock surge to multi-year highs with sector-wide ramifications.
28 May
Clover Health wins lawsuit on Star Ratings, driving stock to record high. Star Ratings lawsuit win strengthens regulatory compliance and lifts Clover Health valuation.
16 May
Clover Health's Q1 earnings call drew analyst questions on revenue growth, cost controls, Medicare Advantage expansion, competitive pressures, and long-term profitability outlook. Analyst questions during earnings calls deliver moderate insights into strategy and risks that can influence near-term investor sentiment.
9 May
Clover Health (CLOV) returns to profitability amid Medicare Advantage growth, prompting a valuation reassessment highlighting improved financials and market potential. Return to profitability and Medicare Advantage expansion represent major positive shifts in financial performance and core operations.
8 May
Clover Health (CLOV) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript provides critical financial metrics, growth strategies, and outlook that could significantly sway investor confidence and stock performance.
7 May
Clover Health Q1 earnings met analyst estimates, sales beat expectations, and membership rose. Beating sales estimates and rising membership indicate strong growth in core operations, likely boosting financial performance and investor sentiment.
Clover Health Investments, Corp. (CLOV) Q1 2026 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Q1 earnings call summary discloses financial performance and strategic outlook, poised to significantly sway CLOV's trajectory and investor sentiment.
6 May
Clover Health Investments released Q1 earnings call highlights covering financial results, operational updates, and forward guidance for the Medicare Advantage insurer. Q1 earnings highlights reveal financial performance and strategic outlook directly shaping CLOV's market trajectory and investor confidence.
Clover Health (NASDAQ:CLOV) reported strong Q1 CY2026 results, surpassing expectations and surprising investors. Strong Q1 earnings surprise indicates major positive shift in financial performance and investor sentiment.
Clover Health Investments, Corp. (CLOV) reported first quarter 2026 results, detailing financial performance, Medicare Advantage enrollment growth, and operational updates. Q1 2026 earnings reveal financial health, revenue, and membership metrics critical to stock valuation and growth trajectory.